| Article
In honor of American Pharmacists Month this October, we want to highlight the essential role healthcare professionals play in managing opioid use disorder (OUD). OUD presents significant challenges, especially when treating patients with concurrent pain. This complexity arises from the delicate...
| Video
Dr. Mark Garofoli discusses a positive stride in advancing patient care and making efforts to ensure that lives within the national opioid crisis are saved and/or improved. One of those positive strides involves the FDA approval of abuse deterrent formulation (ADF) opioid medications, with the aim...
| Article
Abuse deterrent formulations: different manners of preventing someone from transgressing to the inhalation or snorting of medications, or intravenous use.
- Aversion: if someone attempts to abuse the product it would not feel good. For instance, if the product is crushed and snorted, the nose is...
| Video
While abuse deterrent formulations purportedly meet the FDA demand for safer opioid medications, their expense has been rarely supported by third party payors. Dr. Schatman reviews the reimbursement picture, the evidence for their effectiveness, and how prescribers can best respond.
| Article
Dr. Webster and I wrote an article in 2015 about an insurance company’s reluctance to pay for abuse-deterrent formulations of opioids. We continue to opine that insurers would rather see patients with chronic pain, who were expensive to maintain, overdose and die rather than have to pay for...